Please enable JavaScript to continue using this application.

Compare $FATE vs $LCTX | Chartloom

Compare

$FATE vs $LCTX

Fate Therapeutics Inc · Lineage Cell Therapeutics Inc

FATE

Fate Therapeutics Inc

LCTX

Lineage Cell Therapeutics Inc

Compare $FATE vs $LCTX

Comparing Fate Therapeutics Inc and Lineage Cell Therapeutics Inc

FATEFate Therapeutics Inc

LCTXLineage Cell Therapeutics Inc

FATEFate Therapeutics Inc

Market cap

$254M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

54.34x

Rev growth (TTM)

-23.4%

YTD performance

120.2%

52W performance

44.4%

FCF yield

-41.6%

LCTXLineage Cell Therapeutics Inc

Market cap

$248M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.49x

Rev growth (TTM)

-37.1%

YTD performance

-39.4%

52W performance

-42.5%

FCF yield

-10.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

FATE

LCTX

Detailed metrics comparison

FATE

Fate Therapeutics Inc

LCTX

Lineage Cell Therapeutics Inc

Market Cap

FATE$254M

LCTX$248M

Enterprise Value

FATE$234M

LCTX$210M

Price

FATE$2.18

LCTX$0.99

P/E Ratio

FATEN/A

LCTXN/A

P/S Ratio

FATE39.15x

LCTX18.94x

EV/Sales

FATE35.98x

LCTX16.09x

EV/EBITDA

FATE0.00x

LCTX0.00x

P/B Ratio

FATE1.81x

LCTX3.86x

P/FCF Ratio

FATEN/A

LCTXN/A

EV/FCF

FATE-2.21x

LCTX-8.48x

PEG Ratio

FATEN/A

LCTXN/A

Forward P/E (NTM)

FATEN/A

LCTXN/A

Forward P/S (NTM)

FATE54.34x

LCTX28.49x

Revenue (TTM)

FATE$6M

LCTX$13M

Revenue Growth (YoY)

FATE-23.4%

LCTX-37.1%

Forward Rev Growth

FATE-17.6%

LCTX-16.6%

Gross Margin (TTM)

FATE0.0%

LCTX94.1%

Operating Margin (TTM)

FATE0.0%

LCTX0.0%

EBITDA Margin (TTM)

FATE-1873.4%

LCTX-199.6%

Net Margin (TTM)

FATE-1941.1%

LCTX-246.6%

FCF Margin (TTM)

FATE-1627.8%

LCTX-189.7%

Net Income (TTM)

FATE$-126M

LCTX$-32M

FCF (TTM)

FATE$-106M

LCTX$-25M

EPS (TTM)

FATE-$1.05

LCTX-$0.13

ROE (TTM)

FATE-6508.0%

LCTX-7114.0%

ROA (TTM)

FATE-4173.0%

LCTX-3087.0%

ROIC (TTM)

FATE-6174.0%

LCTX-7104.0%

Cash

FATE$32M

LCTX$37M

Debt

FATE$12M

LCTX$48K

Net Cash/Debt

FATE$21M

LCTX$37M

Current Ratio (TTM)

FATE4.85x

LCTX6.61x

Quick Ratio (TTM)

FATE4.74x

LCTX6.44x

Debt/Equity (TTM)

FATE0.08x

LCTX0.00x

Debt/Assets (TTM)

FATE0.0%

LCTX0.0%

Interest Coverage (TTM)

FATEN/A

LCTXN/A

Net Debt/EBITDA (TTM)

FATE0.00x

LCTX0.00x

Beta

FATE2.67

LCTX1.67

52W Performance

FATE44.4%

LCTX-42.5%

YTD Performance

FATE120.2%

LCTX-39.4%

% from 52W High

FATE-32.5%

LCTX-52.4%

% from 52W Low

FATE129.5%

LCTX12.7%

Asset Turnover (TTM)

FATE0.02x

LCTX0.07x

FCF Yield (TTM)

FATE-41.6%

LCTX-10.0%

Earnings Yield (TTM)

FATE-49.6%

LCTX-13.0%

Dividend Yield (TTM)

FATEN/A

LCTXN/A

Rule of 40

FATE-1,651.1

LCTX-226.8

EV/GP/RG

FATEN/A

LCTXN/A

Ticker research

View FATE research View LCTX research

Metric	FATE Fate Therapeutics Inc	LCTX Lineage Cell Therapeutics Inc
Market & Valuation
Market Cap	$254M	$248M
Enterprise Value	$234M	$210M
Price	$2.18	$0.99
P/E Ratio	N/A	N/A
P/S Ratio	39.15x	18.94x
EV/Sales	35.98x	16.09x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.81x	3.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.21x	-8.48x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	54.34x	28.49x
Revenue & Growth
Revenue (TTM)	$6M	$13M
Revenue Growth (YoY)	-23.4%	-37.1%
Forward Rev Growth	-17.6%	-16.6%
Profitability
Gross Margin (TTM)	0.0%	94.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1873.4%	-199.6%
Net Margin (TTM)	-1941.1%	-246.6%
FCF Margin (TTM)	-1627.8%	-189.7%
Net Income (TTM)	$-126M	$-32M
FCF (TTM)	$-106M	$-25M
EPS (TTM)	-$1.05	-$0.13
ROE (TTM)	-6508.0%	-7114.0%
ROA (TTM)	-4173.0%	-3087.0%
ROIC (TTM)	-6174.0%	-7104.0%
Financial Health
Cash	$32M	$37M
Debt	$12M	$48K
Net Cash/Debt	$21M	$37M
Current Ratio (TTM)	4.85x	6.61x
Quick Ratio (TTM)	4.74x	6.44x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.67	1.67
52W Performance	44.4%	-42.5%
YTD Performance	120.2%	-39.4%
% from 52W High	-32.5%	-52.4%
% from 52W Low	129.5%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.07x
FCF Yield (TTM)	-41.6%	-10.0%
Earnings Yield (TTM)	-49.6%	-13.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,651.1	-226.8
EV/GP/RG	N/A	N/A
Ticker research	View FATE research	View LCTX research

Valuation

P/S Ratio

LCTX

18.94x

FATE

39.15x

EV/FCF

LCTX

-8.48x

FATE

-2.21x

Growth & revenue

Revenue Growth TTM

FATE

-23.4%

LCTX

-37.1%

Forward Revenue Growth

LCTX

-16.6%

FATE

-17.6%

Profitability & performance

Gross Margin

LCTX

94.1%

FATE

0.0%

ROE

FATE

-6508.0%

LCTX

-7114.0%

FCF Yield %

LCTX

-10.0%

FATE

-41.6%

52-Week Performance

FATE

44.4%

LCTX

-42.5%

Detailed metrics comparison

FATE

Fate Therapeutics Inc

LCTX

Lineage Cell Therapeutics Inc

Market Cap

FATE$254M

LCTX$248M

Enterprise Value

FATE$234M

LCTX$210M

Price

FATE$2.18

LCTX$0.99

P/E Ratio

FATEN/A

LCTXN/A

P/S Ratio

FATE39.15x

LCTX18.94x

EV/Sales

FATE35.98x

LCTX16.09x

EV/EBITDA

FATE0.00x

LCTX0.00x

P/B Ratio

FATE1.81x

LCTX3.86x

P/FCF Ratio

FATEN/A

LCTXN/A

EV/FCF

FATE-2.21x

LCTX-8.48x

PEG Ratio

FATEN/A

LCTXN/A

Forward P/E (NTM)

FATEN/A

LCTXN/A

Forward P/S (NTM)

FATE54.34x

LCTX28.49x

Revenue (TTM)

FATE$6M

LCTX$13M

Revenue Growth (YoY)

FATE-23.4%

LCTX-37.1%

Forward Rev Growth

FATE-17.6%

LCTX-16.6%

Gross Margin (TTM)

FATE0.0%

LCTX94.1%

Operating Margin (TTM)

FATE0.0%

LCTX0.0%

EBITDA Margin (TTM)

FATE-1873.4%

LCTX-199.6%

Net Margin (TTM)

FATE-1941.1%

LCTX-246.6%

FCF Margin (TTM)

FATE-1627.8%

LCTX-189.7%

Net Income (TTM)

FATE$-126M

LCTX$-32M

FCF (TTM)

FATE$-106M

LCTX$-25M

EPS (TTM)

FATE-$1.05

LCTX-$0.13

ROE (TTM)

FATE-6508.0%

LCTX-7114.0%

ROA (TTM)

FATE-4173.0%

LCTX-3087.0%

ROIC (TTM)

FATE-6174.0%

LCTX-7104.0%

Cash

FATE$32M

LCTX$37M

Debt

FATE$12M

LCTX$48K

Net Cash/Debt

FATE$21M

LCTX$37M

Current Ratio (TTM)

FATE4.85x

LCTX6.61x

Quick Ratio (TTM)

FATE4.74x

LCTX6.44x

Debt/Equity (TTM)

FATE0.08x

LCTX0.00x

Debt/Assets (TTM)

FATE0.0%

LCTX0.0%

Interest Coverage (TTM)

FATEN/A

LCTXN/A

Net Debt/EBITDA (TTM)

FATE0.00x

LCTX0.00x

Beta

FATE2.67

LCTX1.67

52W Performance

FATE44.4%

LCTX-42.5%

YTD Performance

FATE120.2%

LCTX-39.4%

% from 52W High

FATE-32.5%

LCTX-52.4%

% from 52W Low

FATE129.5%

LCTX12.7%

Asset Turnover (TTM)

FATE0.02x

LCTX0.07x

FCF Yield (TTM)

FATE-41.6%

LCTX-10.0%

Earnings Yield (TTM)

FATE-49.6%

LCTX-13.0%

Dividend Yield (TTM)

FATEN/A

LCTXN/A

Rule of 40

FATE-1,651.1

LCTX-226.8

EV/GP/RG

FATEN/A

LCTXN/A

Ticker research

View FATE research View LCTX research

Metric	FATE Fate Therapeutics Inc	LCTX Lineage Cell Therapeutics Inc
Market & Valuation
Market Cap	$254M	$248M
Enterprise Value	$234M	$210M
Price	$2.18	$0.99
P/E Ratio	N/A	N/A
P/S Ratio	39.15x	18.94x
EV/Sales	35.98x	16.09x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.81x	3.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.21x	-8.48x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	54.34x	28.49x
Revenue & Growth
Revenue (TTM)	$6M	$13M
Revenue Growth (YoY)	-23.4%	-37.1%
Forward Rev Growth	-17.6%	-16.6%
Profitability
Gross Margin (TTM)	0.0%	94.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1873.4%	-199.6%
Net Margin (TTM)	-1941.1%	-246.6%
FCF Margin (TTM)	-1627.8%	-189.7%
Net Income (TTM)	$-126M	$-32M
FCF (TTM)	$-106M	$-25M
EPS (TTM)	-$1.05	-$0.13
ROE (TTM)	-6508.0%	-7114.0%
ROA (TTM)	-4173.0%	-3087.0%
ROIC (TTM)	-6174.0%	-7104.0%
Financial Health
Cash	$32M	$37M
Debt	$12M	$48K
Net Cash/Debt	$21M	$37M
Current Ratio (TTM)	4.85x	6.61x
Quick Ratio (TTM)	4.74x	6.44x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.67	1.67
52W Performance	44.4%	-42.5%
YTD Performance	120.2%	-39.4%
% from 52W High	-32.5%	-52.4%
% from 52W Low	129.5%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.07x
FCF Yield (TTM)	-41.6%	-10.0%
Earnings Yield (TTM)	-49.6%	-13.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,651.1	-226.8
EV/GP/RG	N/A	N/A
Ticker research	View FATE research	View LCTX research